Manufacturing Bispecific Antibodies: Development & Scale-Up, Upcoming Webinar Hosted by Xtalks

In this free webinar, learn how bispecific antibody design and process development can affect manufacturability, product quality and scale-up. The featured speaker will discuss chain pairing, cell line development, analytical characterization and purification strategies for removing mispaired and incomplete antibody species. Attendees will also explore how process optimization and characterization can support product consistency as programs advance toward clinical and commercial manufacturing.

TORONTO, Oct. 7, 2026 /PRNewswire/ -- Bispecific antibodies have emerged as a rapidly growing biologic modality that can engage two distinct biological targets within a single molecule. Their unique mechanisms of action have created new opportunities in oncology, immunology and other therapeutic areas, enabling treatment strategies that may not be achievable with traditional monoclonal antibodies. However, the same structural complexity that drives their therapeutic potential also introduces significant development and manufacturing challenges. This webinar explores the critical considerations involved in developing and manufacturing bispecific antibodies, from early-stage process development through commercial scale-up.

The featured speaker will examine how antibody design influences manufacturability, why correct heavy and light chain pairing is essential and the strategies development teams use to promote formation of the desired molecular structure while minimizing product variants.

The session will also examine the role of cell line development, analytical characterization and process optimization in supporting product quality and consistency. Focus will be placed on downstream purification challenges, including the removal of mispaired and incomplete antibody species and the design of chromatography-based purification workflows capable of achieving clinical and commercial purity requirements.

As bispecific antibody programs advance toward larger manufacturing scales, maintaining product consistency becomes increasingly important. The webinar will discuss how process parameters can influence variant distribution and how robust process characterization helps ensure reliable performance during scale-up. The featured speaker will discuss a real-world example of how purification strategies were optimized to improve product purity and support successful transition into clinical manufacturing.

Register for this webinar to learn how bispecific antibodies can be developed and manufactured to address purification, product consistency and scale-up challenges.

Join Dave Briggs, PhD, MSAT Principal Scientist, Late Stage/Commercial, Avid Bioservices, for the live webinar on Monday, October 26, 2026, at 9am PDT (12pm EDT / 5pm CET).

For more information, or to register for this event, visit Manufacturing Bispecific Antibodies: Development & Scale-Up.

ABOUT XTALKS

Xtalks – The Life Science Community™ empowers professionals across pharma, biotech, medtech, healthcare and research with the trusted knowledge and collaborative insights that move the industry forward. Powered by Honeycomb Worldwide Inc., Xtalks delivers news, feature articles, webinars, podcasts, videos, expert interviews, curated job opportunities and more designed to support informed decision-making in a fast-evolving sector.

Every year, thousands of professionals rely on Xtalks for timely intelligence, peer perspectives and industry thought leadership. Join our life science community to stay informed, connected and ready for what's next.

To learn more about Xtalks, visit www.xtalks.com
For information about working with Xtalks to host your webinar, visit https://xtalks.com/partner-with-us/

Contact:
Soumya Shashikumar
Tel: +1 (416) 977-6555 x371
Email: [email protected]

SOURCE Xtalks